Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CASPONEB
2023-508861-34-00Phase 2Authorised
- Sponsor
- CHRU Tours
- Start
- Feb 2025
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of caspofungin in pneumocystis pneumonia (PCP) (2 arms), sponsored by CHRU Tours. Planned start Feb 2025; status: authorised.
02
Drugs
caspofungin
03
Conditions
pneumocystis pneumonia (PCP)
Beyond the preview
Go deeper on 2023-508861-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508861-34-00.